

PLEASE AMEND THE ABOVE-IDENTIFIED APPLICATION AS FOLLOWS:

In The Claims:

Enter replacement claims 245, 265, 266, 267, 275, 276 and 277 as follows:

F¹
245. (Amended) A composition comprising a primary nucleic acid component which upon introduction into a eukaryotic cell produces a secondary nucleic acid component which is capable of producing a nucleic acid product, or a tertiary nucleic acid component, or both, in said eukaryotic cell, wherein said primary nucleic acid component is not obtained with said secondary or tertiary component or said nucleic acid product.

F²
265. (Amended) A composition of matter comprising a nucleic acid component which when present in a cell produces a non-natural nucleic acid product, which product comprises (i) a cellular compartment localizing entity, and (ii) a nucleic acid sequence of interest.

266. (Amended) The composition of claim 265, wherein said cellular compartment localizing entity (i) is sufficient to permit localization of said non-natural nucleic acid product.

267. (Amended) The composition of claim 265, wherein said localizing entity (i) comprises a cytoplasmic or nuclear localization signalling sequence.

275. (Amended) The composition of claim 273, wherein said non-natural nucleic acid product comprises antisense RNA or antisense DNA and said localizing entity (i) comprises a nuclear localization signalling sequence.

3
276. (Amended) The composition of claim 273, wherein said non-natural nucleic acid product comprises antisense RNA or antisense DNA and said localizing entity (i) comprises a cytoplasmic localization signalling sequence.

277. (Amended) The composition of claim 273, wherein said non-natural nucleic acid product comprises sense RNA or sense DNA and said localizing entity (i) comprises a cytoplasmic localization signalling sequence.

✓
Cancel claims 281 and 285.

Add new claims 314-316 as follows:

314. (NEW) A construct which when present in a cell produces a product, said construct being bound non-ionically to an entity comprising a chemical modification or a ligand.

4
315. (NEW) The construct of claim 314, having at least one terminus, said terminus comprising a polynucleotide tail.

316. (NEW) The construct of claim 315, wherein said polynucleotide tail is hybridized to a complementary polynucleotide sequence.
